(CSTL) Castle Biosciences - Ratings and Ratios
Dermatologic, Cancer, Diagnostics, Barretts Esophagus, Mental Health
CSTL EPS (Earnings per Share)
CSTL Revenue
Description: CSTL Castle Biosciences
Castle Biosciences, a pioneering molecular diagnostics company, is revolutionizing the diagnosis and treatment of various dermatologic cancers, Barretts esophagus, uveal melanoma, and mental health conditions through innovative test solutions. The companys comprehensive portfolio includes DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melano
By leveraging advanced gene expression profiling and spatial-omics technologies, Castle Biosciences tests, such as TissueCypher, empower clinicians to make informed decisions and improve patient outcomes. The companys product offerings cater to the skin cancer and gastroenterology markets, capitalizing on the growing demand for precision diagnostics. With a strong foundation established since its incorporation in 2007, Castle Biosciences is poised for continued growth and expansion.
From a technical analysis perspective, CSTLs stock has demonstrated a recent uptrend, with its last price of 19.75 surpassing its 20-day and 50-day simple moving averages. However, the stock remains below its 200-day SMA, indicating a potential long-term downtrend. With an average true range of 0.71, representing a 3.61% fluctuation, the stocks volatility is relatively moderate. Given the current technical setup, a breakout above the 52-week high of 34.67 could signal a strong bullish reversal.
From a fundamental perspective, Castle Biosciences market capitalization stands at 532.41M USD, with a negative return on equity. As a growth-stage company, the absence of a price-to-earnings ratio is expected. However, the companys innovative product pipeline and expanding market presence are expected to drive future revenue growth. Combining the technical and fundamental data, a forecast for CSTL suggests a potential price target of 25.00 in the short term, driven by a breakout above its 200-day SMA and continued growth in its molecular diagnostics business.
With the companys strong product portfolio and expanding market presence, a long-term target of 35.00 is plausible, driven by sustained revenue growth and increasing market share. However, investors should be cautious of the companys negative return on equity and the competitive landscape in the molecular diagnostics industry. A thorough analysis of the companys financials and market trends is necessary to confirm the forecasted price targets.
CSTL Stock Overview
| Market Cap in USD | 621m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-07-25 |
CSTL Stock Ratings
| Growth Rating | -55.4% |
| Fundamental | 58.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -41.2% |
| Analyst Rating | 4.89 of 5 |
CSTL Dividends
Currently no dividends paidCSTL Growth Ratios
| Growth Correlation 3m | 57.7% |
| Growth Correlation 12m | -80% |
| Growth Correlation 5y | -69% |
| CAGR 5y | -5.79% |
| CAGR/Max DD 3y | -0.09 |
| CAGR/Mean DD 3y | -0.21 |
| Sharpe Ratio 12m | -1.00 |
| Alpha | -40.05 |
| Beta | 0.335 |
| Volatility | 80.63% |
| Current Volume | 644.3k |
| Average Volume 20d | 380k |
| Stop Loss | 20.2 (-6.6%) |
| Signal | 0.04 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-9.47m TTM) > 0 and > 6% of Revenue (6% = 20.8m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 1.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 86.00% (prev 97.69%; Δ -11.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 62.5m > Net Income -9.47m (YES >=105%, WARN >=100%) |
| Net Debt (-44.9m) to EBITDA (25.0m) ratio: -1.79 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.5m) change vs 12m ago 2.81% (target <= -2.0% for YES) |
| Gross Margin 80.27% (prev 79.06%; Δ 1.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.10% (prev 59.02%; Δ 8.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -52.75 (EBITDA TTM 25.0m / Interest Expense TTM 331.0k) >= 6 (WARN >= 3) |
Altman Z'' -0.57
| (A) 0.55 = (Total Current Assets 348.7m - Total Current Liabilities 50.9m) / Total Assets 544.7m |
| (B) -0.41 = Retained Earnings (Balance) -221.5m / Total Assets 544.7m |
| (C) -0.03 = EBIT TTM -17.5m / Avg Total Assets 516.0m |
| (D) -2.48 = Book Value of Equity -221.4m / Total Liabilities 89.4m |
| Total Rating: -0.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.12
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 9.67% = 4.84 |
| 3. FCF Margin 9.97% = 2.49 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.46 = 2.34 |
| 6. ROIC - WACC -10.93% = -12.50 |
| 7. RoE -2.11% = -0.35 |
| 8. Rev. Trend 94.83% = 4.74 |
| 9. Rev. CAGR 35.99% = 2.50 |
| 10. EPS Trend 62.55% = 1.56 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CSTL shares?
Over the past week, the price has changed by -10.14%, over one month by +7.62%, over three months by +12.20% and over the past year by -30.15%.
Is Castle Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CSTL is around 19.48 USD . This means that CSTL is currently overvalued and has a potential downside of -9.9%.
Is CSTL a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CSTL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.6 | 64.8% |
| Analysts Target Price | 35.6 | 64.8% |
| ValueRay Target Price | 21.5 | -0.8% |
Last update: 2025-09-16 04:33
CSTL Fundamental Data Overview
CCE Cash And Equivalents = 275.9m USD (Cash And Short Term Investments, last quarter)
P/S = 1.7944
P/B = 1.3645
Beta = 1.074
Revenue TTM = 346.3m USD
EBIT TTM = -17.5m USD
EBITDA TTM = 25.0m USD
Long Term Debt = 8.10m USD (from longTermDebt, last quarter)
Short Term Debt = 3.52m USD (from shortTermDebt, last quarter)
Debt = 11.6m USD (Calculated: Short Term 3.52m + Long Term 8.10m)
Net Debt = -44.9m USD (from netDebt column, last quarter)
Enterprise Value = 357.0m USD (621.4m + Debt 11.6m - CCE 275.9m)
Interest Coverage Ratio = -52.75 (Ebit TTM -17.5m / Interest Expense TTM 331.0k)
FCF Yield = 9.67% (FCF TTM 34.5m / Enterprise Value 357.0m)
FCF Margin = 9.97% (FCF TTM 34.5m / Revenue TTM 346.3m)
Net Margin = -2.73% (Net Income TTM -9.47m / Revenue TTM 346.3m)
Gross Margin = 80.27% ((Revenue TTM 346.3m - Cost of Revenue TTM 68.3m) / Revenue TTM)
Tobins Q-Ratio = -1.61 (set to none) (Enterprise Value 357.0m / Book Value Of Equity -221.4m)
Interest Expense / Debt = 0.18% (Interest Expense 21.0k / Debt 11.6m)
Taxrate = 15.39% (3.32m / 21.6m)
NOPAT = -17.5m (EBIT -17.5m, no tax applied on loss)
Current Ratio = 6.85 (Total Current Assets 348.7m / Total Current Liabilities 50.9m)
Debt / Equity = 0.03 (Debt 11.6m / last Quarter total Stockholder Equity 455.4m)
Debt / EBITDA = 0.46 (Net Debt -44.9m / EBITDA 25.0m)
Debt / FCF = 0.34 (Debt 11.6m / FCF TTM 34.5m)
Total Stockholder Equity = 448.1m (last 4 quarters mean)
RoA = -1.74% (Net Income -9.47m, Total Assets 544.7m )
RoE = -2.11% (Net Income TTM -9.47m / Total Stockholder Equity 448.1m)
RoCE = -3.83% (Ebit -17.5m / (Equity 448.1m + L.T.Debt 8.10m))
RoIC = -3.81% (NOPAT -17.5m / Invested Capital 458.2m)
WACC = 7.12% (E(621.4m)/V(633.0m) * Re(7.25%)) + (D(11.6m)/V(633.0m) * Rd(0.18%) * (1-Tc(0.15)))
Shares Correlation 3-Years: 87.88 | Cagr: 1.06%
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 71.37% ; FCFE base≈31.0m ; Y1≈21.2m ; Y5≈10.5m
Fair Price DCF = 7.02 (DCF Value 203.8m / Shares Outstanding 29.0m; 5y FCF grow -37.01% → 3.0% )
EPS Correlation: 62.55 | EPS CAGR: 0.0% | SUE: 1.49 | # QB: True
Revenue Correlation: 94.83 | Revenue CAGR: 35.99%
Additional Sources for CSTL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle